CPRX


Analyst Predicts Success for Catalyst Pharmaceutical (CPRX ) Stock Following News of Latest FDA Approval

Catalyst Pharmaceutical (CPRX) stock fell about 8% between Thursday and Friday. Even though the company just announced its first FDA approval for Firdapse, …

Catalyst Pharmaceuticals (CPRX): A Biotech Stock This Analyst Is Closely Watching

Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it’s receiving updates from an important clinical trial or hearing …

Catalyst Pharmaceuticals (CPRX): We Are Confident of Firdapse’s Approvability, Says Analyst

Catalyst Pharmaceuticals (NASDAQ:CPRX) is expecting the FDA to rule on its marketing application for Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert …

Oppenheimer Pounds the Table on Catalyst Pharmaceuticals (CPRX) Ahead of Upcoming FDA Decision

Oppenheimer analyst Leland Gershell was out pounding the table on shares of Catalyst Pharmaceuticals (CPRX), reiterating a Buy rating and price target of $6.00, which implies …

Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX)

Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX) and AcelRx Pharmaceuticals (ACRX) look forward to important regulatory approval decisions this year. Could these catalysts give these small …

Cantor Sees Strong Upside in Catalyst Pharmaceuticals (CPRX) Shares, Sets an $8 Price Target

Many investors hope to win big on biotech stocks as shares can skyrocket when there is good news. With that in mind, Cantor …

Why Catalyst Pharmaceuticals (CPRX) Is a $6 Stock

Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have been waiting for two-and-a-half years since its marketing application was originally submitted to see the company’s flagship candidate …